



## The Past, Present, and Future of mRNA Vaccines

Guest Editor:

**Prof. Dr. Norbert Pardi**  
Department of Medicine,  
University of Pennsylvania,  
Philadelphia, PA, USA

Deadline for manuscript  
submissions:  
**closed (1 January 2021)**

### Message from the Guest Editor

Vaccines represent one of the most successful interventions of modern medicine. Currently used vaccine types have many shortfalls, and, thus, the development of next-generation vaccines that are safe, easy-to-produce, and offer broad and durable protection against a wide range of pathogens and have the ability to eliminate various types of cancer is urgently needed. mRNA vaccines have the potential to meet these criteria and, thus, represent one of the most promising new generation vaccine modalities.

This Special Issue of *Vaccines* will provide a series of peer-reviewed perspective and review articles that discuss the current standing and speculate on the future of the field of mRNA vaccines. This Special Issue will discuss a broad range of topics including recent developments in various types of infectious disease and cancer mRNA vaccines, passive immunization with mRNA, delivery materials, and production of mRNA vaccines, among other topics.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)